Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII

A small animal model for humans with high responder inhibitor phenotype

M. A. Jarvis, L. G. Levin, J. A. Harrison, D. J. DePianto, C. M. Suzuki, C. L. Ziaja, J. E. Brown, K. W. Jolly, H. M. Reisner, C. F. Abildgaard, Jerry S Powell

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Hemophilia A is a clotting disorder that is due to reduced or absent coagulation factor VIII (FVIII) activity. In approximately 25% of people with severe hemophilia A, standard treatment with intravenous plasma-derived or recombinant FVIII (rFVIII) induces anti-FVIII antibodies that inhibit FVIII activity (inhibitors). We describe the development of a rat model to study the formation of inhibitors. Immunization of rats with human rFVIII in adjuvant induced an anti-human rFVIII antibody response characteristic of an anti-FVIII inhibitor response in hemophilia A patients. The rats exhibited a rapid, polyclonal secondary antibody response to human rFVIII. These antibodies were reactive against epitopes located in the heavy and light chains. All the rFVIII-immunized rats developed antibodies against the FVIII C2 domain, a region of major reactivity in hemophilia A patients with inhibitors. Furthermore, competition ELISAs demonstrated that rat and human anti-FVIII antibodies recognized identical or overlapping epitopes of the FVIII molecule. The rat anti-FVIII antibodies also functioned as human FVIII inhibitors with titers ranging from 120 to 2048 Bethesda Units (B.U.). We propose that this rat model may be useful to investigate immune responses to FVIII and may lead to better therapies for FVIII inhibitors.

Original languageEnglish (US)
Pages (from-to)318-325
Number of pages8
JournalThrombosis and Haemostasis
Volume75
Issue number2
StatePublished - Feb 1996

Fingerprint

Factor VIII
Immunization
Animal Models
Phenotype
Hemophilia A
Antibodies
Antibody Formation
Epitopes
human F8 protein
Enzyme-Linked Immunosorbent Assay
Light

ASJC Scopus subject areas

  • Hematology

Cite this

Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII : A small animal model for humans with high responder inhibitor phenotype. / Jarvis, M. A.; Levin, L. G.; Harrison, J. A.; DePianto, D. J.; Suzuki, C. M.; Ziaja, C. L.; Brown, J. E.; Jolly, K. W.; Reisner, H. M.; Abildgaard, C. F.; Powell, Jerry S.

In: Thrombosis and Haemostasis, Vol. 75, No. 2, 02.1996, p. 318-325.

Research output: Contribution to journalArticle

Jarvis, MA, Levin, LG, Harrison, JA, DePianto, DJ, Suzuki, CM, Ziaja, CL, Brown, JE, Jolly, KW, Reisner, HM, Abildgaard, CF & Powell, JS 1996, 'Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: A small animal model for humans with high responder inhibitor phenotype', Thrombosis and Haemostasis, vol. 75, no. 2, pp. 318-325.
Jarvis, M. A. ; Levin, L. G. ; Harrison, J. A. ; DePianto, D. J. ; Suzuki, C. M. ; Ziaja, C. L. ; Brown, J. E. ; Jolly, K. W. ; Reisner, H. M. ; Abildgaard, C. F. ; Powell, Jerry S. / Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII : A small animal model for humans with high responder inhibitor phenotype. In: Thrombosis and Haemostasis. 1996 ; Vol. 75, No. 2. pp. 318-325.
@article{4986bf49abfe4e7c855da8fff1548db8,
title = "Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: A small animal model for humans with high responder inhibitor phenotype",
abstract = "Hemophilia A is a clotting disorder that is due to reduced or absent coagulation factor VIII (FVIII) activity. In approximately 25{\%} of people with severe hemophilia A, standard treatment with intravenous plasma-derived or recombinant FVIII (rFVIII) induces anti-FVIII antibodies that inhibit FVIII activity (inhibitors). We describe the development of a rat model to study the formation of inhibitors. Immunization of rats with human rFVIII in adjuvant induced an anti-human rFVIII antibody response characteristic of an anti-FVIII inhibitor response in hemophilia A patients. The rats exhibited a rapid, polyclonal secondary antibody response to human rFVIII. These antibodies were reactive against epitopes located in the heavy and light chains. All the rFVIII-immunized rats developed antibodies against the FVIII C2 domain, a region of major reactivity in hemophilia A patients with inhibitors. Furthermore, competition ELISAs demonstrated that rat and human anti-FVIII antibodies recognized identical or overlapping epitopes of the FVIII molecule. The rat anti-FVIII antibodies also functioned as human FVIII inhibitors with titers ranging from 120 to 2048 Bethesda Units (B.U.). We propose that this rat model may be useful to investigate immune responses to FVIII and may lead to better therapies for FVIII inhibitors.",
author = "Jarvis, {M. A.} and Levin, {L. G.} and Harrison, {J. A.} and DePianto, {D. J.} and Suzuki, {C. M.} and Ziaja, {C. L.} and Brown, {J. E.} and Jolly, {K. W.} and Reisner, {H. M.} and Abildgaard, {C. F.} and Powell, {Jerry S}",
year = "1996",
month = "2",
language = "English (US)",
volume = "75",
pages = "318--325",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "2",

}

TY - JOUR

T1 - Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII

T2 - A small animal model for humans with high responder inhibitor phenotype

AU - Jarvis, M. A.

AU - Levin, L. G.

AU - Harrison, J. A.

AU - DePianto, D. J.

AU - Suzuki, C. M.

AU - Ziaja, C. L.

AU - Brown, J. E.

AU - Jolly, K. W.

AU - Reisner, H. M.

AU - Abildgaard, C. F.

AU - Powell, Jerry S

PY - 1996/2

Y1 - 1996/2

N2 - Hemophilia A is a clotting disorder that is due to reduced or absent coagulation factor VIII (FVIII) activity. In approximately 25% of people with severe hemophilia A, standard treatment with intravenous plasma-derived or recombinant FVIII (rFVIII) induces anti-FVIII antibodies that inhibit FVIII activity (inhibitors). We describe the development of a rat model to study the formation of inhibitors. Immunization of rats with human rFVIII in adjuvant induced an anti-human rFVIII antibody response characteristic of an anti-FVIII inhibitor response in hemophilia A patients. The rats exhibited a rapid, polyclonal secondary antibody response to human rFVIII. These antibodies were reactive against epitopes located in the heavy and light chains. All the rFVIII-immunized rats developed antibodies against the FVIII C2 domain, a region of major reactivity in hemophilia A patients with inhibitors. Furthermore, competition ELISAs demonstrated that rat and human anti-FVIII antibodies recognized identical or overlapping epitopes of the FVIII molecule. The rat anti-FVIII antibodies also functioned as human FVIII inhibitors with titers ranging from 120 to 2048 Bethesda Units (B.U.). We propose that this rat model may be useful to investigate immune responses to FVIII and may lead to better therapies for FVIII inhibitors.

AB - Hemophilia A is a clotting disorder that is due to reduced or absent coagulation factor VIII (FVIII) activity. In approximately 25% of people with severe hemophilia A, standard treatment with intravenous plasma-derived or recombinant FVIII (rFVIII) induces anti-FVIII antibodies that inhibit FVIII activity (inhibitors). We describe the development of a rat model to study the formation of inhibitors. Immunization of rats with human rFVIII in adjuvant induced an anti-human rFVIII antibody response characteristic of an anti-FVIII inhibitor response in hemophilia A patients. The rats exhibited a rapid, polyclonal secondary antibody response to human rFVIII. These antibodies were reactive against epitopes located in the heavy and light chains. All the rFVIII-immunized rats developed antibodies against the FVIII C2 domain, a region of major reactivity in hemophilia A patients with inhibitors. Furthermore, competition ELISAs demonstrated that rat and human anti-FVIII antibodies recognized identical or overlapping epitopes of the FVIII molecule. The rat anti-FVIII antibodies also functioned as human FVIII inhibitors with titers ranging from 120 to 2048 Bethesda Units (B.U.). We propose that this rat model may be useful to investigate immune responses to FVIII and may lead to better therapies for FVIII inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=9044240476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044240476&partnerID=8YFLogxK

M3 - Article

VL - 75

SP - 318

EP - 325

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 2

ER -